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A B S T R A C T
Background
Cystic fibrosis (CF) a life-limiting inherited disease affecting a number of organs, but classically associated with chronic lung infection
and progressive loss of lung function. Chronic infection by Burkholderia cepacia complex (BCC) is associated with increased morbidity
and mortality and therefore represents a significant challenge to clinicians treating people with CF. This review examines the current
evidence for long-term antibiotic therapy in people with CF and chronic BCC infection.
Objectives
The objective of this review is to assess the effects of long-term oral and inhaled antibiotic therapy targeted against chronic BCC lung
infections in people with CF. The primary objective is to assess the efficacy of treatments in terms of improvements in lung function
and reductions in exacerbation rate. Secondary objectives include quantifying adverse events, mortality and changes in quality of life
associated with treatment.
Search methods
We searched the Cochrane Cystic Fibrosis Trials Register, compiled from electronic database searches and handsearching of journals
and conference abstract books. We also searched online trial registries and the reference lists of relevant articles and reviews.
Date of last search: 29 May 2019.
Selection criteria
Randomised controlled trials (RCTs) of long-term antibiotic therapy in people with CF and chronic BCC infection.
Data collection and analysis
Two authors independently extracted data, assessed risk of bias and assessed the quality of the evidence using GRADE.
Main results
We included one RCT (100 participants) which lasted 52 weeks comparing continuous inhaled aztreonam lysine (AZLI) and placebo
in a double-blind RCT for 24 weeks, followed by a 24-week open-label extension and a four-week follow-up period. The average
participant age was 26.3 years, 61% were male and average lung function was 56.5% predicted.
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Treatment with AZLI for 24 weeks was not associated with improvement in forced expiratory volume in one second (FEV1), mean
difference 0.91% (95% confidence interval (CI) -3.15 to 4.97) (moderate-quality evidence). The median time to the next exacerbation
was 75 days in the AZLI group compared to 51 days in the placebo group, but the difference was not significant (P = 0.27) (moderate-
quality evidence). Similarly, the number of participants hospitalised for respiratory exacerbations showed no difference between groups,
risk ratio (RR) 0.88 (95% CI 0.53 to 1.45) (moderate-quality evidence). Overall adverse events were similar between groups, RR 1.08
(95% CI 0.98 to 1.19) (moderate-quality evidence). There were no significant differences between treatment groups in relation to
mortality (moderate-quality evidence), quality of life or sputum density.
In relation to methodological quality, the overall risk of bias in the study was assessed to be unclear to low risk.
Authors’ conclusions
We found insufficient evidence from the literature to determine an effective strategy for antibiotic therapy for treating chronic BCC
infection.
P L A I N L A N G U A G E S U M M A R Y
Antibiotic treatments for long-term Burkholderia cepacia infections in people with cystic fibrosis
Review question
We reviewed the evidence for long-term antibiotic treatments for people with cystic fibrosis who are infected with Burkholderia cepacia
complex (bacteria composed of at least 20 different species).
Background
People with cystic fibrosis often suffer from repeated chest infections and eventually their lungs become permanently infected by
bacteria, such as a family of bacteria called Burkholderia cepacia complex which can cause problems because many antibiotics do not
work against them and they can cause a quicker deterioration in lung disease. We wanted to discover whether using long-term antibiotic
treatment was beneficial for people with cystic fibrosis and Burkholderia cepacia complex infection.
Search date
The evidence is current to: 29 May 2019.
Study characteristics
This review included one study of 100 people aged between 6 and 57 years old. The study compared an inhaled antibiotic called
aztreonam to placebo (a substance which contains no medication) and people were selected for one treatment or the other randomly
(by chance). The study lasted 52 weeks.
Key results
The only study included in this review found inhaled aztreonam had no beneficial effect on lung function or rates of chest infections
in people with cystic fibrosis and Burkholderia cepacia complex infection. There was no difference between groups in relation to the
average time to the next exacerbation or the number of people hospitalised for an exacerbation. Overall adverse events were similar
between groups and with regards to other outcomes assessed, there was no difference between treatment groups for mortality, quality
of life or sputum density. More research is needed to establish if other inhaled antibiotics may be useful.
Quality of the evidence
Overall quality of evidence was considered to be moderate across all outcomes, which means further research is likely to have an
important impact on results.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
AZLI compared with placebo for chronic Burkholderia cepacia complex infection in people with CF
Patient or population: adults and children with CF
Settings: CF treatment centres across North America
Intervention: AZLI for inhalat ion 75 mg three t imes a day via nebuliser for 24 weeks
Comparison: placebo, three t imes a day via nebuliser for 24 weeks
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo AZLI
Relat ive change in
FEV1%predicted
The mean change in
FEV1 (% predicted) in
the control group was -
0.75%
The mean change in
FEV1 (% predicted) in
the intervent ion group
was0.91% higher ( 3.
15% lower to 4.97%
higher)
NA 99 (1 study) ⊕⊕⊕©
Moderate1
Days to next exacerba-
t ion
See comment NA 100 (1 study) ⊕⊕⊕©
Moderate1
Median days to next ex-
acerbat ion in the con-
trol group was 75 days.
Median days to next ex-
acerbat ion in the inter-
vent ion group was 24
days lower.
Part icipants hos-
pitalised for respiratory
exacerbat ion
400 per 1000 352 per 1000
(212 to 580)
RR 0.88 (95%CI 0.53 to
1.45)
100 (1 study) ⊕⊕⊕©
Moderate1
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Any AEs 904 per 1000 976 per 1000 (886 to
1076)
RR 1.08 (95%CI 0.98 to
1.19)
100 (1 study) ⊕⊕⊕©
Moderate1
Wheeze was more f re-
quent in the AZLI group
compared to placebo
but groups were other-
wise well matched
Mortality There were 0 deaths in
the placebo group
There were 2 deaths in
the intervent ion arm
RR 5.41 (95%CI 0.27 to
109.87)
100 (1 study) ⊕⊕⊕©
Moderate1
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
AE: adverse event; AZLI: aztreonam lysine for inhalat ion; CF: cyst ic f ibrosis; CI: conf idence interval; FEV1: f orced expiratory volume in one second; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate
1Downgraded once due to imprecision of results (small sample size and subsequent wide intervals)
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B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is a life-threatening inherited disease affecting
over 10,000 people in the UK, 35,000 in Europe and 30,000
in the USA (CFF 2016; CF Trust 2017; Farrell 2008). There
have been significant improvements in CF survival since the 1930s
when 70% of those with CF died in infancy, to a current median
predicted survival of 43.5 years (CF Trust 2017). Early CF deaths
are now rare: over 95% of children with CF enter adulthood and
recent predictions are that by 2025, the number of CF adults in
Europe will have nearly doubled (Burgel 2015).
In CF, the genetic autosomal-recessive defect in the CFTR protein
causes abnormal salt and water movements across mucus-produc-
ing cell surfaces. This results in thick mucus leading to a combi-
nation of infection and inflammation with subsequent local organ
damage, which is most apparent in the lungs and pancreas, but
affects many other organs. In the lungs the hallmarks of disease are
chronic airway inflammation and chronic infection with difficult
to treat pathogens, such as Pseudomonas aeruginosa, Staphylococcus
aureus and Burkholderia cepacia complex (BCC). Chronic airway
infection is associated with a progressive loss of lung function,
which is the primary cause of death in people with CF (Corey
1997).
BCC is comprised of a group of over 20 closely related species
with a cumulative annual prevalence in people with CF of 3%
to 5%; Burkholderia cenocepacia and Burkholderia multivorans
account for 85% to 97% of BCC infections (CFF 2016; CF
Trust 2017; Drevinek 2010;Mahenthiralingam 2002; Vandamme
2011). These two pathogens are associated with poor outcomes
including accelerated pulmonary decline, a necrotizing pneumo-
nia known as ’cepacia syndrome’ and a higher mortality rate (Aris
2001; Mahenthiralingam 2002; Zlosnik 2015). B cenocepacia is
the more pathogenic of the two, with an increased likelihood of
chronic infection and reduced survival compared to B multivo-
rans (Jones 2004; Mahenthiralingam 2001). Acquisition is often
from environmental sources, but clonal transmission of epidemic
strains has been extensively reported, particularly forB cenocepacia,
and hence infection control and segregation measures are required
to prevent cross-infection (Ledson 1998; LiPuma 2010; Zlosnik
2015).
Resistance to aminoglycosides, to most beta-lactams as well as to
polymyxins is common within BCC and some species have the
ability to develop resistance to any agent resulting in pan-resistant
strains (CF Trust 2017;Drevinek 2010;Mahenthiralingam 2002).
Therefore, the clinical management of chronic BCC infection in
CF poses a challenge to clinicians.
Description of the intervention
Long-term antibiotics are one of the mainstays of treatment in
people with CF with chronic infection, these are usually inhaled
or given orally to reduce the bacterial burden in sputum. Inhaled
antibiotics allow rapid deposition of high concentrations of an-
tibiotics direct to the site of action and hence represent an attrac-
tive strategy. In those with P aeruginosa infection, colistimethate,
tobramycin and aztreonam have all demonstrated clinical benefit
(Gibson 2003; McCoy 2008; Retsch-Bogart 2008; Ryan 2011).
The low systemic absorption associated with inhaled antibiotics
can help avoid some of the side-effects seen with intravenous an-
tibiotics used in acute infection (Weber 1995). Oral antibiotics
are quick and convenient to take, but may not be able to deliver
as high a concentration to the lung as inhaled formulations. Nev-
ertheless, oral macrolide therapy has been shown to be effective in
CF with a recent Cochrane Review demonstrating a reduction in
pulmonary exacerbations and improved respiratory function after
six months treatment of azithromycin (Southern 2012).
How the intervention might work
Long-term antibiotic therapy targeted towards P aeruginosa infec-
tions has been associated with improved clinical outcomes in peo-
ple with CF and both inhaled and oral antibiotic therapies are rec-
ommended in that cohort (NICE 2017). There is no clear guid-
ance on whether treatments targeted towards BCC are effective,
but inhaled antibiotics may theoretically overcome traditional re-
sistance breakpoints due the 100-fold increase in concentrations
achieved in the lung. Hence antimicrobial agents, with little or
no activity against BCC at systemically achievable concentrations,
may still exert bactericidal effects when inhaled into the lungs
(Ramsey 1999).
Furthermore,macrolides have no in vitro bactericidal effect against
P aeruginosa, yet appear to producemarked clinical improvements.
This is most likely secondary to an anti-inflammatory effect with
attenuated cytokine production and reductions in neutrophil elas-
tase reported in a number of studies (Bell 2005; Wales 1999).
Hence, despite BCC often demonstrating in vitro resistance to
many of the antimicrobial agents available for chronic use in CF,
there is hope that the principles of treatment and agents used in
chronic P aeruginosa infection are relevant in BCC infection.
Why it is important to do this review
Chronic infection with BCC is associated with poorer clinical out-
comes in people with CF. The inherent antibiotic resistance in
these species makes the treatment of chronic infection challeng-
ing for clinicians. This review aims to assess the current evidence
with regards to antibiotic treatment options for people with CF
who are chronically infected with BCC to identify evidence-based
strategies.
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Strategies will primarily be assessed in terms of their ability to
preserve or improve pulmonary function and to reduce acute pul-
monary exacerbations.
O B J E C T I V E S
The objective of this review is to assess the effects of long-term oral
and inhaled antibiotic therapy targeted against chronic BCC lung
infections in people with CF. The primary objective is to assess the
efficacy of treatments in terms of improvements in lung function
and reductions in exacerbation rate. Secondary objectives include
quantifying adverse events, mortality and changes in quality of life
(QoL) associated with treatment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs), including those with a cross-
over design, were considered for inclusion in this review.
Types of participants
Adults and children with CF (confirmed by either a positive sweat
test or the identification of two pathogenic CFTRmutations) and
chronic BCC infection (defined as a positive respiratory culture
growth of BCC within the last six months and BCC growth in
more than 50% of all respiratory cultures in the last 12 months)
(Lee 2003).
Types of interventions
Long-term (defined as a period of eight weeks or more) antibiotics
(all agents, doses and regimens) via either the inhaled or oral route.
Studies were included if there was comparison to either no treat-
ment, placebo, another antibiotic agent, anothermode of delivery,
or another dose or regimen of the same antibiotic.
Types of outcome measures
Primary outcomes
1. Lung function
i) forced expiratory volume in one second (FEV1)
a) absolute change in volumes, % predicted or both
b) relative change in volumes, % predicted or both
2. Pulmonary exacerbations
i) time to next exacerbation
ii) hospitalisations
iii) exacerbation rate
iv) IV antibiotic use
3. Adverse events
i) mild: transient event, no treatment change, e.g. rash,
nausea, diarrhoea
ii) moderate: treatment discontinued, e.g. nephrotoxicity,
ototoxicity, hepatitis, visual impairment
iii) severe: causing hospitalisation or death
Secondary outcomes
1. Mortality
2. QoL
i) validated QoL score, e.g. CFQ-R Respiratory
Symptom Score (RSS)
3. BCC culture
i) sputum density of BCC
4. Changes in inflammatory markers
i) sputum or bronchoalveolar lavage (BAL) samples
ii) serum or blood
Search methods for identification of studies
We searched for all relevant published and unpublished studies
without restrictions on language, year or publication status.
Electronic searches
The Cochrane Cystic Fibrosis and Genetic Disorders Group’s In-
formation Specialist conducted a systematic search of the Group’s
Cystic Fibrosis Trials Register for relevant trials using the following
terms: Burkholderia cepacia OR mixed infections.
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of the Cochrane Library),
weekly searches ofMEDLINE, a search of Embase to 1995 and the
prospective handsearching of two journals - Pediatric Pulmonology
and the Journal of Cystic Fibrosis. Unpublished work is identified
by searching through the abstract books of three major cystic fi-
brosis conferences: the International Cystic Fibrosis Conference;
the European Cystic Fibrosis Conference and theNorth American
Cystic Fibrosis Conference. For full details of all searching activ-
ities for the register, please see the relevant sections of the Cystic
Fibrosis and Genetic Disorders Group website.
Date of the most recent search of the Group’s Cystic Fibrosis Trials
Register: 29 May 2019.
We searched the following trials registries:
• the World Health Organization (WHO) International
Clinical Trials Registry Platform ( www.who.int/trialsearch)
(searched 29 May 2019);
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• Clinicaltrials.gov ( www.clinicaltrials.gov) (searched 29
May 2019).
See an appendix for details of the searches (Appendix 1).
Searching other resources
We checked the bibliographies of included studies and any rele-
vant systematic reviews identified for further references to relevant
studies.
Data collection and analysis
Selection of studies
Two review authors (FF, DN) independently selected studies to
be included in the review. Where there was disagreement on the
suitability of a study for inclusion, all three review authors reached
a consensus decision after discussion.
Data extraction and management
Each author independently extracted data using standardised data
collection forms. We planned to compare outcome measures at
eight weeks to three months, over three months to six months and
over six months to one year. However, we planned that should we
identify studies with outcome data at alternative time-points, we
would also consider these. We planned to analyse oral and inhaled
antibiotics separately, however, we found no relevant studies of
oral antibiotics.
Assessment of risk of bias in included studies
Each review author independently assessed studies following the
domain-based evaluation as described in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011a). Briefly, a
judgement of ’low risk’, ’high risk’ or ’unclear risk’ of bias was
made for each of the seven domains in the Cochrane tool which
are listed below.
• Random sequence generation
• Allocation concealment
• Blinding of participant personnel
• Blinding of outcome assessment
• Incomplete outcome data
• Selective reporting
• Other sources of bias
In the case of any disagreements between the three review authors,
we aimed to reach a consensus by discussion.
Measures of treatment effect
For continuous outcomes, such as change in lung function we cal-
culated themean difference (MD) with corresponding 95% confi-
dence intervals (CI) to measure treatment effect. If there had been
more than one study included, which reported multiple variations
of a similar outcome, we planned to calculate the standardized
mean difference (SMD) and corresponding 95% CIs.
For dichotomous outcomes such as mortality, we calculated risk
ratios (RR) and corresponding CIs.
For the included studies, where SEs were reported (e.g. relative
change for FEV1%predicted), in order to enter the data into ’Data
and analyses’ we calculated the SD using the formula: SD = SE x
square root of n.
Unit of analysis issues
No cross-over studies were included in the review. In future up-
dates of this review, should cross-over studies be included we plan
to include data from cross-over studies should the duration of
treatment meet the inclusion criteria and if the relevant informa-
tion, as described by Elbourne is available (Elbourne 2002). In
such cases we plan to treat the studies as parallel studies and pool
the intervention arms to be compared against the control arms, or
alternatively perform analysis on the first period only, depending
on the information available.
Dealing with missing data
We assessed for missing data in reported results and report the
percentage of participants from whom no outcome data were ob-
tained on the data collection form. Unless there is reason to sus-
pect data are not missing at random, we included data on only
those whose results are known in the analysis and use the total
participants with complete data as the denominator rather than
the total number of participants (Higgins 2011b).
Assessment of heterogeneity
There were insufficient studies to assess heterogeneity, however
should more studies be conducted in the future we plan to assess
heterogeneity of inconsistencies across studies using the I² statistic
and interpret the I² statistic based on the thresholds of heterogene-
ity set out by Higgins (Higgins 2003):
• 0% to 40%: might not be important;
• 30% to 60%: may represent evidence of moderate
heterogeneity;
• 50% to 90%: may represent evidence of substantial
heterogeneity;
• 75% to 100%:may represent evidence of considerable
heterogeneity.
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Assessment of reporting biases
If we are able to include more studies in the future, we will attempt
to assess whether our review is subject to publication bias by using
a funnel plot; if we detect asymmetry, we will explore causes other
than publication bias.
Data synthesis
When sufficient data are available we plan to assess whether studies
are clinically similar enough to combine into meta-analyses, and if
so, we will assess for heterogeneity as outlined above. If we identify
at least substantial heterogeneity (higher than 50%), we will use a
random-effects model, otherwise, we will use a fixed-effect model.
Subgroup analysis and investigation of heterogeneity
We planned to conduct a subgroup analysis on species (B ceno-
cepacia and B multivorans), however, we were unable to do so due
to lack of studies and data. In future updates of this review, when
possible, we plan to consider the potential effects of the intermit-
tent use of acute antibiotics by undertaking a subgroup analysis.
Sensitivity analysis
If there are sufficient studies in future updates of this review (10
or more) we will review the validity of our conclusions by carrying
out sensitivity analyses to assess the influence of a high risk of bias
(any domain) on our results and conclusions and the effects of a
fixed-effect analysis versus a random-effects analysis. This has not
been possible to date due to a lack of eligible studies.
Summary of findings table
We prepared a summary of findings table for the included com-
parison. We included reported changes in the primary outcomes
FEV1 (changes in relative % predicted or volumes or both), time
to next exacerbation and hospitalisations, mortality and adverse
events (mild, moderate and severe). We listed population, setting,
intervention and comparison and reported an illustrative risk for
the experimental and control intervention with MDs re-expressed
as RRs as required (Schünemann 2011b). The grade of quality
for each outcome was adjudicated as moderate using the Grading
of Recommendations Assessment, Development and Evaluation (
GRADE) ( Schunemann 2006).
R E S U L T S
Description of studies
Results of the search
We identified a total of 144 references from the search of the Cys-
tic Fibrosis and Genetic Disorders Group’s Cystic Fibrosis Trials
Register. We identified no further studies from the searches of in-
ternational trials databases. After initial consideration, we found
114 not to be relevant and we discounted these (Figure 1). We
examined the remaining six studies (18 references), and included
one study (12 references) and excluded five studies (six references)
(Characteristics of included studies; Characteristics of excluded
studies).
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Figure 1. Study flow diagram.
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Included studies
We included a placebo-controlled RCT of long-term nebulised
aztreonam lysine (AZLI), which was funded by the makers of
AZLI (Tullis 2014). In this study, 100 participants were included
(52 AZLI, 48 placebo) across 35 adult and paediatric centres in
North America. A total of 61% of participants were male, with
ages ranging from 6 years to 57 years old.
Participants were randomised to receive either 24 weeks of con-
tinuous treatment of nebulised AZLI 75 mg three times a day or
placebo. The primary endpoint was mean change in FEV1 % pre-
dicted. Key secondary outcomes were number of days to antibi-
otic use for respiratory exacerbations, hospitalisations, respiratory
symptoms and change in sputummicrobiology. A blindedmedical
reviewer adjudicated whether the use of antibiotics and hospital-
isations were due to respiratory exacerbations. No restrictions on
additional antibiotic use were imposed.
Excluded studies
A total of five studies were excluded. Two studies were excluded as,
on further examination, they were not RCTs (Kun 1984; Waters
2017); two studies did not concern the population under review
(Adeboyeku 2001; Burns 1999); and one study design did not
include a relevant intervention (Ledson 2002) (Characteristics of
excluded studies).
Risk of bias in included studies
The overall risk of bias in the included study was assessed as ’low’.
The study authors did report industry funding; however, the ran-
domisation, blinding and outcome adjudication procedures were
all conducted and reported appropriately. Further details can be
found in the Characteristics of included studies and in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
Sequence generation
The included study stratified randomisation by region. The au-
thors justified this approach as an attempt to mitigate different
treatment-centre approaches for managing chronic Burkholderia
species infection. Participants were assigned randomly 1:1 to ei-
ther treatment or placebo. The sequence generation method is not
reported and the risk of bias is therefore unclear.
Allocation concealment
Allocation concealment was not reported and we therefore judged
the study to have an unclear risk of bias.
Blinding
Participants, investigators and outcome adjudicators were all
blinded to allocation. Risk of bias was therefore considered to be
low for this domain.
Incomplete outcome data
The included study reported that 14 participants (14%) did not
continue treatment for the 24-week study period, given the nature
of the study population this does not seem excessive. Primary out-
come data are reported for all participants; however, the primary
outcomes results were adjusted to account for completed days in
the study. One secondary outcome was reported for less than half
of all participants (change in Burkholderia species sputum density
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at week 24), which the authors reported was due to inability to
provide a sputum sample of sufficient quality for sputum density
analysis. Risk of bias was therefore considered to be unclear for
this domain.
Selective reporting
After review of the manuscript, supplementary material and prior
results presented at conferences we found no evidence of selective
reporting of outcomes. There was no statistical analysis of differ-
ences in safety outcomes reported. Our own analysis confirmed
no overall difference in adverse events. The risk of bias for this
domain was therefore considered to be low.
Other potential sources of bias
No other potential sources of bias were identified.
Effects of interventions
See: Summary of findings for themain comparison Summary of
findings - AZLI compared with placebo for chronic Burkholderia
cepacia complex infection in people with CF
The quality of the evidence has been graded for those outcomes
included in the summary of findings table. For the definitions
of these gradings, please refer to the summary of findings table
(Summary of findings for the main comparison).
AZLI versus placebo
One study (100 participants) was included in the review (Tullis
2014).
Primary outcomes
1. Lung function
a. FEV1
i. Absolute change in volumes, % predicted or both
The included study did not report this outcome.
ii. Relative change in volumes, % predicted or both
The study reported the relative change in % predicted FEV1 from
baseline to week 24, expressed as the mean area under curve cor-
rected for baseline and adjusted for number of days on study. There
was no statistically significant difference between the groups, MD
0.91% (95% -3.15 to 4.97) (moderate-quality evidence) (Analysis
1.1).
2. Pulmonary exacerbations
a. Time to next exacerbation
The included study reported median days to next antibiotic use
for respiratory exacerbation (as adjudicated by a blinded medical
reviewer). The estimated number of median days to next antibi-
otic use was for 24 days fewer in the placebo arm, however, this
difference was not statistically significant (P = 0.266).
b. Hospitalisations
Total number of respiratory hospitalisations, number of days hos-
pitalised for respiratory exacerbations, number and proportion of
participants hospitalised at least once, and respiratory hospitalisa-
tion rate per participant year were all reported. At 24 weeks, no
statistically significant differences were reported, RR 0.88 (95%
CI 0.53 to 1.45) (Analysis 1.2).
c. Exacerbation rate
Exacerbation rate was not reported.
d. IV antibiotic use
IV antibiotic use was not reported separately. Instead a composite
of number of unique days of IV, oral or inhaled antibiotics (or
both) was reported. There were no statistically significant differ-
ences reported.
3. Adverse events
Adverse events were reported in detail, however, no statistical anal-
ysis of differences between groups is reported in the original paper.
Our own analysis revealed no statistically significant differences in
overall adverse events between groups (Analysis 1.4) (Summary of
findings for the main comparison).
a. mild: transient event, no treatment change, e.g. rash,
nausea, diarrhoea
The study reported a number of mild adverse events (cough, spu-
tum increase, pyrexia, oropharyngeal pain, dyspnoea, haemopty-
sis, chest discomfort, nasal congestion, nausea, fatigue, wheezing,
decreased appetite, rhinorrhoea, sinus congestion, sinus headache,
chest pain, lung disorder, respiratory tract congestion, chills,
headache and rales). At 24 weeks, wheeze was statistically signif-
icantly higher in the AZLI group compared to placebo, RR 3.61
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(95% CI 1.06 to 12.34) (Analysis 1.4), however other common
adverse events including cough (RR 1.15 (95% CI 0.87 to 1.52)),
dyspnoea (RR 1.01 (95% CI 0.55 to 1.87)) and increased sputum
(RR 1.25 (95% 0.79 to 1.96)) were all similar. It was noted in the
trial report that “...The wheezing observed among AZLI-treated
subjects appeared to be associated with underlying disease (asthma
or prior history of wheezing), was associated with a viral infection,
or was one of multiple symptoms reported for acute pulmonary
exacerbation...”.
b. moderate: treatment discontinued, e.g. nephrotoxicity,
ototoxicity, hepatitis, visual impairment
At 24 weeks, the study reported no difference between treatment
groups, there were five participants in the AZLI arm who discon-
tinued due to adverse events, no discontinuations were seen in the
placebo group, RR 11.90 (95% CI 0.68 to 209.61) (Analysis 1.4).
c. severe: causing hospitalisation or death
The study reported that severe adverse events mainly consisted
of respiratory exacerbations and were similar between groups at
24 weeks, RR 1.08 (95% CI 0.49 to 2.37) (Analysis 1.4). Other
severe adverse events included one life-threatening adverse event
(respiratory failure) and two deaths, all of which occurred in the
AZLI treatment group.
Secondary outcomes
1. Mortality
Mortality was reported in crude rates. Our own analysis revealed
no statistically significant differences between groups at 24 weeks,
RR 5.41 (95% CI 0.27 to 109.87) (Analysis 1.5).
2. QoL
a. Validated QoL score (e.g. CFQ-R, CRISS score)
Relative change from baseline to week 24 for the CFQ-R respira-
tory symptoms scale score was presented; no significant differences
were reported, MD 0.18 (95% CI -4.37 to 4.73) (Analysis 1.6).
3. BCC culture
a. Sputum density of BCC
The authors presented the average change in Log10 Burkholderia
species CFU/g sputum from baseline to week 24. No significant
differences were reported (at 24 weeks), MD 0.93 (95% -0.57
to 2.43); however, it was noted that this analysis included only
15 participants in the AZLI group and 20 in the placebo group
(Analysis 1.7).
4. Changes in inflammatory markers
a. Sputum or bronchoalveolar lavage (BAL) samples
The included study did not report this outcome.
b. Serum or blood
The included study did not report this outcome.
D I S C U S S I O N
Summary of main results
The aim of this review was to assess the evidence for the long-
term antibiotic therapy for chronic infection with BCC. Despite
extensive searches of the literature we were only able to include one
study suitable for inclusion in the review (Summary of findings for
the main comparison). The included study compared 24 weeks
of AZLI with placebo in people with CF and chronic BCC in-
fection. The study appeared well-conducted and reported most of
the outcomes of interest to this review. There were no statistically
significant differences between treatment groups and placebo in
terms of lung function or exacerbations. AZLI appeared to be gen-
erally well-tolerated, however, wheeze was significantly higher in
the AZLI group compared to placebo.
Overall completeness and applicability of
evidence
As we were only able to include one study in this review, there is
a clear need for more evidence in this field. The included study
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investigated the use of one intervention in a broad group of par-
ticipants. The availability of an increasing array of nebulised an-
tibiotics for people with CF warrants further trials of their use in
this population.
Quality of the evidence
We were only able to include one study, which, although well-
conducted, makes it likely that further studies may change the
estimated effect size. Given the quality of evidence was assessed to
be moderate across all outcomes, future research is likely to have
an important impact on our estimates and conclusions.
Agreements and disagreements with other
studies or reviews
There are no other reviews in this setting and little in the way of
observational data. Our findings of a general lack of evidence for
the treatment of chronicBCC infection are in keepingwith reviews
of other aspects of care of people withCF andBCC (Horsley 2016;
Regan 2019).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found insufficient evidence from the literature to determine
an effective strategy for antibiotic therapy in chronic Burkholderia
cepacia complex infection.
Implications for research
Although the included study did not report any positive findings,
it served to confirm that large randomised controlled trials can
be performed in this population. The high concurrent antibiotic
use in the included study may make the exacerbation outcomes
difficult to define and difficult to compare with other studies.
The recent expansion in available nebulised antibiotics, as well
as products currently in clinical trial phase should mean further
clinical trials are feasible in the future.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Tullis 2014
Methods RCT
Conducted in 35 centres (USA: 34; Canada:1 (Feb 2010 - Sept 2011)
Participants 100 participants (48 given AZLI treatment; 52 given placebo)
Eligible participants ≥ 6 years of age had documented CF and chronic infection with
Burkholderia spp.
61 participants were male
Interventions 24 weeks of continuous treatment with 75 mg inhaled AZLI (3 times a day) or placebo
Followed by a 24-week extension period of open-label AZLI treatment for all participants
(weeks 24 - 48); and a 4-week follow-up period (weeks 48 - 52)
Outcomes Primary outcome was change in lung function (FEV1) at 24 weeks
Secondary outcomes included: number of respiratory exacerbations requiring IV, oral or
inhaled antibiotics (or both); number of respiratory hospitalisations; AUCave through
week 24 for CF Questionnaire-Revised (CFQ-R) Respiratory Symptoms scores; time to
respiratory exacerbation requiring IV, oral or inhaled antibiotics (or both); and adverse
events
Notes The study was funded by Gilead Sciences
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not clear how sequences were generated
Allocation concealment (selection bias) Unclear risk Not clear how allocation was concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blinded with identical placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded medical reviewer for subjective
outcomes
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Some outcomes reported with significantly
reduced participants. Overall, 84% of par-
ticipants completed the trial and continued
onto the extension period)
Selective reporting (reporting bias) Low risk No evidence of selective reporting
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Tullis 2014 (Continued)
Other bias Low risk No other potential sources of bias were
identified
AUCave : average area under the curve
AZLI: aztreonam lysine
FEV1: forced expiratory volume in one second
RCT: randomised controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adeboyeku 2001 Not relevant participants
Burns 1999 Not relevant participants
Kun 1984 Not a RCT
Ledson 2002 Not a relevant intervention
Waters 2017 Not a RCT
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. AZLI versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in FEV1 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 At 24 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Participants hospitalised for
respiratory exacerbation
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 At 24 weeks 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Overall adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 At 24 weeks 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Adverse events (by severity) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Mild: cough 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Mild: wheeze 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Mild: dyspnoea 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 Mild: sputum increased 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 Moderate: discontinuation 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.6 Severe: severe adverse
events or life-threatening
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Mortality 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 At 24 weeks 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 QoL 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 At 24 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Sputum density of BCC 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 At 24 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 AZLI versus placebo, Outcome 1 Change in FEV1.
Review: Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis
Comparison: 1 AZLI versus placebo
Outcome: 1 Change in FEV1
Study or subgroup AZLI Control
Mean
Difference
Mean
Difference
N Mean(SD)[%] N Mean(SD)[%] IV,Fixed,95% CI IV,Fixed,95% CI
1 At 24 weeks
Tullis 2014 47 0.16 (10.28) 52 -0.75 (10.3) 0.91 [ -3.15, 4.97 ]
-10 -5 0 5 10
Favours AZLI Favours placebo
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Analysis 1.2. Comparison 1 AZLI versus placebo, Outcome 2 Participants hospitalised for respiratory
exacerbation.
Review: Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis
Comparison: 1 AZLI versus placebo
Outcome: 2 Participants hospitalised for respiratory exacerbation
Study or subgroup AZLI Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 24 weeks
Tullis 2014 17/48 21/52 0.88 [ 0.53, 1.45 ]
0.2 0.5 1 2 5
Favours AZLI Favours placebo
Analysis 1.3. Comparison 1 AZLI versus placebo, Outcome 3 Overall adverse events.
Review: Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis
Comparison: 1 AZLI versus placebo
Outcome: 3 Overall adverse events
Study or subgroup AZLI Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 24 weeks
Tullis 2014 47/48 47/52 1.08 [ 0.98, 1.19 ]
0.2 0.5 1 2 5
Favours AZLI Favours placebo
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Analysis 1.4. Comparison 1 AZLI versus placebo, Outcome 4 Adverse events (by severity).
Review: Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis
Comparison: 1 AZLI versus placebo
Outcome: 4 Adverse events (by severity)
Study or subgroup AZLI Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mild: cough
Tullis 2014 34/48 32/52 1.15 [ 0.87, 1.52 ]
2 Mild: wheeze
Tullis 2014 10/48 3/52 3.61 [ 1.06, 12.34 ]
3 Mild: dyspnoea
Tullis 2014 14/48 15/52 1.01 [ 0.55, 1.87 ]
4 Mild: sputum increased
Tullis 2014 23/48 20/52 1.25 [ 0.79, 1.96 ]
5 Moderate: discontinuation
Tullis 2014 5/48 0/52 11.90 [ 0.68, 209.61 ]
6 Severe: severe adverse events or life-threatening
Tullis 2014 10/48 10/52 1.08 [ 0.49, 2.37 ]
0.005 0.1 1 10 200
Favours AZLI Favours placebo
Analysis 1.5. Comparison 1 AZLI versus placebo, Outcome 5 Mortality.
Review: Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis
Comparison: 1 AZLI versus placebo
Outcome: 5 Mortality
Study or subgroup AZLI Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 24 weeks
Tullis 2014 2/48 0/52 5.41 [ 0.27, 109.87 ]
0.001 0.01 0.1 1 10 100 1000
Favours AZLI Favours placebo
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Analysis 1.6. Comparison 1 AZLI versus placebo, Outcome 6 QoL.
Review: Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis
Comparison: 1 AZLI versus placebo
Outcome: 6 QoL
Study or subgroup AZLI Placebo
Mean
Difference
Mean
Difference
N
Mean(SD)[CFQ-
R RSS] N
Mean(SD)[CFQ-
R RSS] IV,Fixed,95% CI IV,Fixed,95% CI
1 At 24 weeks
Tullis 2014 45 2.97 (11.4039) 52 2.79 (11.3935) 0.18 [ -4.37, 4.73 ]
-10 -5 0 5 10
Favours AZLI Favours placebo
Analysis 1.7. Comparison 1 AZLI versus placebo, Outcome 7 Sputum density of BCC.
Review: Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis
Comparison: 1 AZLI versus placebo
Outcome: 7 Sputum density of BCC
Study or subgroup AZLI Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 24 weeks
Tullis 2014 15 1.41 (2.24) 20 0.48 (2.23) 0.93 [ -0.57, 2.43 ]
-4 -2 0 2 4
Favours AZLI Favours placebo
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A P P E N D I C E S
Appendix 1. Search strategies - trial registries
Registry Search terms
WHO ICTRP Search terms: burkholderia OR cepacia
ClinicalTrials.gov Advanced Search form
Condition or disease : cystic fibrosis
Other terms: burkholderia OR cepacia
Study type: Interventional Studies (Clinical Trials)
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